Table of Contents
Thrombosis
Volume 2013 (2013), Article ID 762310, 5 pages
http://dx.doi.org/10.1155/2013/762310
Review Article

The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty

Department of Orthopaedic Surgery, University of Texas Southwestern Medical Center, 1801 Inwood Road, Dallas, TX 75390-8883, USA

Received 11 September 2012; Accepted 24 January 2013

Academic Editor: C. Arnold Spek

Copyright © 2013 Robert D. Russell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. H. Xing, G. Morrison, W. Lim, J. Douketis, A. Odueyungbo, and M. Crowther, “Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials,” Thrombosis Research, vol. 123, no. 1, pp. 24–34, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Falck-Ytter, C. W. Francis, N. A. Johanson et al., “Prevention of VTE in orthopedic surgery patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, supplement, no. 2, pp. e278S–e325S, 2012. View at Publisher · View at Google Scholar
  3. M. H. Huo, D. L. Spencer, B. J. Borah et al., “Post-discharge venous thromboembolism and bleeding in a large cohort of patients undergoing total hip or total knee arthroplasty,” Journal of Clinical Outcomes Management, vol. 19, no. 8, pp. 355–363, 2012. View at Google Scholar
  4. J.-M. Januel, G. Chen, C. Ruffieux et al., “Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review,” Journal of the American Medical Association, vol. 307, no. 3, pp. 294–303, 2012. View at Publisher · View at Google Scholar
  5. R. H. White, H. Zhou, and P. S. Romano, “Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures,” Thrombosis and Haemostasis, vol. 90, no. 3, pp. 446–455, 2003. View at Google Scholar · View at Scopus
  6. M. Khatod, M. C. Inacio, S. A. Bini, and E. W. Paxton, “Prophylaxis against pulmonary embolism in patients undergoing total hip arthroplasty,” Journal of Bone and Joint Surgery, vol. 93, no. 19, pp. 1767–1772, 2011. View at Google Scholar · View at Scopus
  7. S. S. Jameson, S. C. Charman, P. J. Gregg, M. R. Reed, and J. H. van der Meulen, “The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry,” Journal of Bone and Joint Surgery, vol. 93 B, no. 11, pp. 1465–1470, 2011. View at Publisher · View at Google Scholar
  8. B. T. Bjørnarå, T. E. Gudmundsen, and O. E. Dahl, “Frequency and timing of clinical venous thromboembolism after major joint surgery,” Journal of Bone and Joint Surgery, vol. 88, no. 3, pp. 386–391, 2006. View at Google Scholar
  9. R. J. Friedman, A. S. Gallus, F. D. Cushner, G. FitzGerald, and F. A. Anderson Jr., “Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 87–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Schuringa and D. Yen, “Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty,” Canadian Journal of Surgery, vol. 42, no. 5, pp. 360–362, 1999. View at Google Scholar · View at Scopus
  11. D. Warwick, R. J. Friedman, G. Agnelli et al., “Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry,” Journal of Bone and Joint Surgery B, vol. 89, no. 6, pp. 799–807, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and R. J. Portman, “Apixaban or enoxaparin for thromboprophylaxis after knee replacement,” The New England Journal of Medicine, vol. 361, no. 6, pp. 594–604, 2009, Erratum in: The New England Journal of Medicine, vol. 361, no. 18, p.1814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick, “Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial,” The Lancet, vol. 375, no. 9717, pp. 807–815, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. R. Lassen, A. Gallus, G. E. Raskob, G. Pineo, D. Chen, and L. M. Ramirez, “Apixaban versus enoxaparin for thromboprophylaxis after hip replacement,” The New England Journal of Medicine, vol. 363, no. 26, pp. 2487–2498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2178–2185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. B. I. Eriksson, O. E. Dahl, N. Rosencher et al., “Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial,” The Lancet, vol. 370, no. 9591, pp. 949–956, 2007, Erratum in: The Lancet, vol. 370, no. 9604, p.2004, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. RE-MOBILIZE Writing Committee, J. S. Ginsberg, B. L. Davidson et al., “Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery,” Journal of Arthroplasty, vol. 24, no. 1, pp. 1–9, 2009. View at Publisher · View at Google Scholar
  18. B. I. Eriksson, L. C. Borris, R. J. Friedman et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2765–2775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. K. Kakkar, B. Brenner, O. E. Dahl et al., “Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial,” The Lancet, vol. 372, no. 9632, pp. 31–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. R. Lassen, W. Ageno, L. C. Borris et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty,” The New England Journal of Medicine, vol. 358, no. 26, pp. 2776–2786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. G. Turpie, M. R. Lassen, B. L. Davidson et al., “Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial,” The Lancet, vol. 373, no. 9676, pp. 1673–1680, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. V. Huisman, D. J. Quinlan, O. E. Dahl, and S. Schulman, “Enoxaparin versus Dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analyses of phase III multicenter randomized trials,” Circulation, vol. 3, no. 6, pp. 652–660, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Trkulja and R. Kolundžic, “Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on metaanalysis of pivotal clinical trials,” Croatian Medical Journal, vol. 51, no. 2, pp. 113–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. “Xarelto Prescribing Information,” 2012, http://www.xarelto-us.com/.
  25. B. I. Eriksson, D. J. Quinlan, and J. I. Weitz, “Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development,” Clinical Pharmacokinetics, vol. 48, no. 1, pp. 1–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Kubitza, M. Becka, W. Mueck et al., “Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor,” British Journal of Clinical Pharmacology, vol. 70, no. 5, pp. 703–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck, “Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects,” Journal of Clinical Pharmacology, vol. 47, no. 2, pp. 218–226, 2008, Erratum in:Journal of Clinical Pharmacology, vol. 48, no. 11, p.1366–1367, 2008. View at Google Scholar · View at Scopus
  28. R. J. Friedman, “Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials,” Orthopedics, vol. 34, no. 10, pp. 795–804, 2011. View at Publisher · View at Google Scholar
  29. A. G. Turpie, M. R. Lassen, A. K. Kakkar et al., “Pooled analysis of four studies of rivaroxaban: effect on symptomatic events and bleeding and the influence of clinically relevant patient subgroups,” Chest, vol. 136, meeting abstracts, p. 144, 2009. View at Google Scholar
  30. A. G. Turpie, M. R. Lassen, B. I. Eriksson et al., “Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies,” Thrombosis and Haemostasis, vol. 105, no. 3, pp. 444–453, 2011. View at Publisher · View at Google Scholar
  31. N. G. Espada, R. G. Merino, and T. C. González, “Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials,” Thrombosis Research, vol. 130, no. 2, pp. 183–191, 2012. View at Publisher · View at Google Scholar
  32. C. D. Jensen, A. Steval, P. F. Partington, M. R. Reed, and S. D. Muller, “Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study,” Journal of Bone and Joint Surgery B, vol. 93, no. 1, pp. 91–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Lützner, L. Donath, L. Tittl et al., “Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry,” Thrombosis and Haemostasis, vol. 109, no. 1, pp. 154–163, 2013. View at Publisher · View at Google Scholar